The Academy is now accepting nominations for available 2020-21 positions on the Board of Directors and the Nominating Committee, as well as for 2020 Annual Meeting Awards. The deadline to submit nominations is August 25.
Erchonia Corporation announces another successful clinical trial that has resulted in the granting of an FDA 510(k) market clearance for chronic low back pain of musculoskeletal origin. This grants another first for Erchonia, which started the low-level laser category in January 2002. That year, the FDA issued its first 510(k) market clearance for any low-level laser based on Erchonia's clinical trial for chronic neck and shoulder pain.
Using opioids for acute pain can lead to long-term use and associated morbidity and mortality. Injury has been documented as a gateway to long-term opioid use in some populations, but data are limited for injured workers.
A clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the first Utahns have been treated in its nationwide clinical study of IDCT, a locally developed injectable disc cell therapy for degenerative disc disease (DDD).
The purpose was to evaluate the influence of disordered sleep on the relationship between pain and healthcare utilization (HCU) and pain-related disability and HCU in individuals with low back pain (LBP).